Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test

Journal of Medical Virology

Volumn 83, Issue 2, 2011, Pages 272-276

  Pista, Angela ^a   Verdasca, Nuno ^a   Oliveira, Ana ^a  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

CLART Human Papillomavirus 2; Genotyping; HC2; HPV; Screening

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CLART HUMAN PAPILLOMAVIRUS 2 ASSAY; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYBRID CAPTURE 2 TEST; INTERMETHOD COMPARISON; NONHUMAN; PAPILLOMAVIRUS INFECTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 2;

EID: 78650339175     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21952     Document Type: Article

References (21)

1. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers E-M. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79.
2. Bosch FX, de Sanjose S. 2003. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31: 3-13.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. 1995. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 87: 796-802.
4. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasias grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370: 1764-1772.
5. Castle PE, Solomon D, Schiffman M, Wheeler CM. 2005. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97: 1066-1071.
6. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. 2003. Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet 362: 1871-1876.
7. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26: K29-K41.
8. Halfon P, Benmoura D, Khiri H, Penaranda G, Blanc B, Riggio D, Sandri MT. 2010. Comparison of the clinical performance of carcinogenic HPV typing of the linear array and Papillocheck® HPV-screening assay. J Clin Virol 47: 38-42.
9. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BI, Suntum M, Bock JE, Poll PA, Meijer CJ. 2002. Type-specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population-based prospective follow-up study. BMJ 325: 572-576.
10. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kivial NB. 1992. A cohort study of the risk of cervical intraepithelial neoplasias grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327: 1272-1278.
11. Lai CH, Chang CJ, Huang HJ, Hsueh S, Chao A, Yang JE, Lin CT, Huang SL, Hong JH, Chou HH, Wu TI, Huang KG, Wang CC, Chang TC. 2007. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol 25: 3628-3634.
12. Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch X, Cuzick J, Dillner J, Heideman DAM, Snijders PJF. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124: 516-520.
13. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
14. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. 1999. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 354: 20-25.
15. Renshaw A. 2002. Measuring sensitivity in gynaecologic cytology: A review. Cancer 96: 210-217.
16. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R. 2008. New technologies for cervical cancer screening working group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100: 492-501.
17. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Walcholder S, Stanton SK, Manos MM. 1993. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: 958-964.
18. Schopp B, Holz B, Zago M, Stubenrauch F, Petry KU, Kru S, Iftner T. 2010. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J Med Virol 82: 605-615.
19. Snijders PJF, van den Brule AJC, Meijer CJ. 2003. The clinical relevance of human papillomavirus testing: Relationship between analytical and clinical sensitivity. J Pathol 201: 1-6.
20. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17: 3033-3042.
21. Wentzensen N, Schiffman M, Dunn ST, Zuna RE, Walker J, Allen RA. 2009. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1, 700 women referred to colposcopy in Oklahoma. Int J Cancer 124: 964-969.